US Pharma MarketingA new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competitor emerged.
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competitor emerged.
Source: BioPharma Dive